Current Molecular Biology Reports

, Volume 4, Issue 2, pp 101–115 | Cite as

Epigenetic Regulation in Prostate Cancer Progression

  • Katia Ruggero
  • Sonia Farran-Matas
  • Adrian Martinez-Tebar
  • Alvaro AytesEmail author
Open Access
Molecular Biology of Prostate Cancer (M Kruithof-de Julio, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Molecular Biology of Prostate Cancer


Purpose of Review

An important number of newly identified molecular alterations in prostate cancer affect gene encoding master regulators of chromatin biology epigenetic regulation. This review will provide an updated view of the key epigenetic mechanisms underlying prostate cancer progression, therapy resistance, and potential actionable mechanisms and biomarkers.

Recent Findings

Key players in chromatin biology and epigenetic master regulators has been recently described to be crucially altered in metastatic CRPC and tumors that progress to AR independency. As such, epigenetic dysregulation represents a driving mechanism in the reprograming of prostate cancer cells as they lose AR-imposed identity.


Chromatin integrity and accessibility for transcriptional regulation are key features altered in cancer progression, and particularly relevant in nuclear hormone receptor-driven tumors like prostate cancer. Understanding how chromatin remodeling dictates prostate development and how its deregulation contributes to prostate cancer onset and progression may improve risk stratification and treatment selection for prostate cancer patients.


Prostate cancer Epigenetics Transcriptional regulation Chromatin biology Androgen receptor Drug targets 


Prostate cancer has traditionally been seen as an aging-associated, low mutational load tumor with a tendency for genomic rearrangements and a particular dependency on the activity of the androgen receptor (AR). As such, treatment strategies have been focused on targeting the AR axis, either through inhibiting steroidogenic pathways and the production of testosterone, or by antagonizing the AR itself to prevent its nuclear translocation and the activation of its transcriptional network. While these strategies have doubtlessly improved survival for prostate cancer patients, they are not curative in many cases, and resistance eventually occurs in about 30% of patients, who develop castration-resistant prostate tumors (CRPC) for which limited treatment options exist. Moreover, under the CRPC definition, a pool of diverse disease presentations with variable outcomes exists, including neuroendocrine tumors.

Massive parallel sequencing of hundreds of tumor specimens from prostate cancer patients at different stages of cancer progression has provided an accurate picture of the landscape of genetic alterations that accompany cancer evolution in the prostate. Yet, despite several molecular classification systems for prostate tumors have been proposed, clear association with risk stratification remains to be provided. On the other hand, whether these genetic classifiers predict treatment outcome and to what extent genetic alterations in prostate cancer can be exploited for personalized therapies is yet to be proven. Interestingly, together with well-known drivers of cancer progression, an important number of new alterations have been described, with an intriguing enrichment of those affecting key players in chromatin biology and epigenetic master regulators (see a summary in Table 1). This is particularly relevant in metastatic CRPC and tumors that have transitioned to AR-independent phenotypes after progressing on the newest antiandrogen drugs.
Table 1

Summary of epigenetic master regulators implicated in prostate cancer

Gene name

Function in prostate cancer




H3K36 di-methyltransferase. Promotes prostate cancer tumorigenesis and progression. It is overexpressed in metastatic stage and associated with biochemical recurrence

[1••, 2, 3]


H3K27 di- and tri-methyltransferase. Member of the polycomb repressive complex 2, crucial driver of prostate oncogenesis

[4, 5]

 SUV39H1 (KMT1A)


H3K9 tri methyltransferase. Enhance prostate cancer cell migration and invasion

[6, 7]

 SUV39H2 (KMT1B)

H3K9 tri methyltransferase increases androgen-dependent transcriptional activity by interacting with the AR



H3K4 di- and methyltransferase, promotes cell proliferation and migration

[9, 10].


Drives prostate cancer cell growth through epigenetic inactivation of several tumor suppressors through histone arginine methylation at H4R3. Enhances AR-targeted gene expression

[11, 12•, 13]



H3K9 and H3K4 demethylase involved in prostate cancer recurrence, CRPC, and poor survival. Regulates AR transcriptional activity in a context-dependent manner

[14••, 15, 16•]


H3K4 mono, di-, and tri-demethylase. AR coactivator regulating its transcriptional activity. Upregulated in prostate cancer tissues

[17, 18],


H3K4 di- and tri-demethylase overexpressed in prostate cancer. Proposed as a predictive marker for therapy failure in patients after prostatectomy



H3K4 di- and tri-demethylase. Suppress invasion and progression of prostate cancer. Low levels were associated with poor prognosis and resistance to docetaxel

[20, 21]


H3K9, H3K27, and H4K20 demethylase. Transcriptional coactivator of AR. Promotes prostate cancer cell proliferation, migration, invasion, and neuroendocrine differentiation. Its expression highly correlated with poor prognosis and is induced by hypoxia

[22, 23, 24, 25, 26, 27, 28, 29]


H3K9 and H3K36 tri demethylases. Modulates AR transcriptional activity stimulating ligand-independent gene transcription via H3K9 demethylation

[30, 31]


H3K9 mono- and di-demethylase. Regulates AR activity by recruitment to target genes only in the presence of androgens

[32, 33]


H3K9 tri-demethylase, AR coactivator. Regulates AR transcriptional activity via demethylation activity and via inhibition of ubiquitination and increased AR stability



H3K27 di- and tri-demethylase overexpressed in metastatic prostate cancer


DNA methylation


Control of transcriptional program during prostate cancer and CRPC progression



Silencing of GSP1 upon promoter hypermethylation is a potential prognostic biomarker and occurs early during prostate carcinogenesis

[37, 38, 39]

Histone acetylation


Histone acetyltransferase. Besides canonical histone acetylation activity, it acetylates the AR and enhances its transcriptional activity (coactivator) and drives prostate cancer growth

[40, 41]


Histone deacetylase; regulates cellular growth through AR deacetylation

[42, 43].


Histone deacetylase; its downregulation has been associated with increased acetylated H3K18 and poorer outcome and decreased sensitivity to androgen deprivation therapy


BET bromodomain epigenetic readers


Bromodomain and extra-terminal protein, interacts with AR and promote its activity and antiandrogen resistance

[45•, 46, 47, 48]


Epigenetic reader and transcription co-regulator, overexpressed in CRPC and associated to disease recurrence. Required for prostate cancer cell proliferation in CRPC



H3K4me2-3 epigenetic reader whose loss is related with prostate cancer aggressiveness and DNA repair defects, thus sensitizing tumor cells to PARP inhibitors

[50, 51]

Pioneer transcription factors


FOXA1 activity on chromatin results in increased accessibility and increased chromatin-bound AR. High FOXA1 expression leads to a restricted AR cistrome regulation. FOXA1 also has the potential to reprogram GATA2

[52, 53]


GATA2 activity in human prostate cancer is strongly associated to AR levels and is hence considered a prostate cancer oncogene

[53, 54, 55]

Epigenetic regulators of lineage plasticity


Overexpressed TF in prostate cancer, regulating CRPC proliferation, and evasion of apoptosis. Promotes tumor metastasis by inducing EMT. Associated to NEPC emergence

[56, 57, 58, 59, 60, 61, 62••, 63••]


Master regulator of prostate cancer transcriptional program. Associated with prostate cancer recurrence and poor prognosis

[64, 65]


Driver of NEPC by inducing an EZH2-mediated transcriptional program

[64, 66]

Oncogenic pathways


Initiates ERK signaling and leads to the recruitment of EZH2 to the E-cadherin promoter and repression of E-cadherin expression, driving EMT and invasion in prostate cancer cells



Tumor suppressor Ras-GAP. Negatively controls Ras-dependent mitogenic signals and modulates TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptors pathways

[68, 69, 70].


This tumor suppressor gene is commonly loss in metastatic and antiandrogen resistant prostate cancer and NEPC. Directly repress the expression of Sox2 and Ezh2

[71, 72, 63••]


Tyrosine kinase correlated with poor prognosis and interacts with AR to drive ADT resistance and CRPC growth. Regulates transcription of AR and AR-v7 via epigenetic regulation

[72, 73, 74]

Here, we introduce key concepts to understand how epigenetic dysregulation is a plausible driving mechanism in the reprograming of prostate cancer cells as they lose AR-imposed identity. Beyond reviewing the current status of epigenetic biomarkers and classifiers and their clinical impact, we will discuss the scientific basis for therapeutic targeting master regulators of chromatin remodeling and integrity and the current state of epigenetic drugs for prostate cancer.

DNA Methylation and Histone Modifications in Prostate Carcinogenesis

Perturbed DNA methylation patterns have long been reported during prostate cancer progression [75]. Among the most well-described alterations is the GSTP1 promoter hypermethylation and subsequent silencing [37], which is thought to occur early during prostate carcinogenesis [38] and has thus been proposed as a potential prognostic biomarker [39]. Yet, numerous other key genes have been implicated in DNA methylation changes. In fact, the promoter of the Androgen Receptor (AR) itself appears to be hypermethylated in up to 30% of CRPCs, resulting in the loss of AR expression [76]. Moreover, PTEN silencing is often a consequence of promoter CpG islands hypermethylation [77], while hypermethylation of the p16 tumor suppressor gene is associated with a proliferative advantage, thus contributing to carcinogenesis and disease progression [78]. Similarly, the hypomethylation and consequent upregulation of genes like heparanase and urokinase plasminogen activator (uPA) was reported to contribute to tumor cell invasion and metastasis [79]. More globally, DNA methylation signatures have been identified and proposed as molecular biomarkers of prostate cancer progression and treatment response [80].

Histone modifications also play an important role in the progression of many tumor types including prostate cancer. Lysine methyltransferases (KMT) and demethylases (KDM) are important epigenetic histone modifiers implicated in the control of gene transcriptional regulation as well as in non-histone protein posttranslational modifications and activity modulation [81]. More specifically, SUV39H1 (KMT1A) and SETDB1 (KMT1E) have been shown to enhance prostate cancer cell migration and invasion and to be upregulated in human prostate cancer specimens, and hence suggested as potential therapeutic targets [6], while SUV39H2 (KMT1B) interacts with the AR to increase androgen-dependent transcriptional activity [8]. Furthermore, levels of SETDB1 have been recently associated with prognosis and the development of bone metastases from prostate cancer [7]. Similarly, SET and MYND domain-containing protein 3 (SMYD3) has also been identified as an upregulated H3 and H4 lysine methyltransferase promoting cell proliferation and migration, thus emerging as a predictive marker of prostate cancer [10]. Alternatively, protein arginine methyltransferase 5 (PRMT5) was described as a prostate cancer oncogene driving cancer cell growth through epigenetic inactivation of several tumor suppressors [11] through histone arginine methylation at H4R3. PRMT5 has also recently been shown to enhance AR-targeted gene expression by arginine methylation and interaction with the transcription factor Sp1 [13].

Demethylases also play an important role in prostate cancer development. Lysine-specific demethylase 1 (LSD1/KDM1A) has been proposed as an oncogene whose overexpression has been positively correlated with the malignancy of many cancer types, including prostate [14••, 82], promoting carcinogenesis by multiple mechanisms. Increased LSD1 expression is associated with prostate cancer recurrence and poor survival and appears to have distinct functions in androgen-dependent [14••, 83] and refractory prostate cancer [15]. Recently, it was discovered that LSD1 is a co-regulator of vitamin D receptor activity in prostate cancer and its expression is correlated with shorter progression-free survival in primary and metastatic patients [84]. In a recent study, it was found that LSD1-mediated epigenetic reprogramming drives CRPC and was associated with the activation of CENPE, which was regulated by the co-binding of LSD1 and AR to its promoter region, which was associated with loss of RB1 [16•].

The overexpression of other histone demethylases (HDMs) has also been observed in prostate cancer. An exhaustive functional screen [27] identified 32 enzymes belonging to the family of JmjC domain-containing histone demethylases as critical for prostate cancer proliferation and survival. KDM5 family members are H3K4 demethylases; JARID1B (KDM5B) is upregulated in prostate cancer tissues and acts as an AR coactivator [17], while JARID1C (KDM5C), overexpressed in prostate cancer, emerged as a predictive marker for therapy failure in patients after prostatectomy [19]. JARID1D (KMD5D) was found to suppress the invasion and progression of prostate cancer cells; thus, it is highly downregulated in metastatic prostate tumors and those low levels were associated with poor prognosis [20]. In addition, KDM5 loss has been associated with resistance to docetaxel in prostate cancer [21]. The PHD-finger protein 8 (PHF8) is a histone demethylase and a transcriptional coactivator of AR via H4K20 demethylation [28]. Its expression, highly correlated with poor prognosis, is induced by hypoxia and promotes prostate cancer cell proliferation, migration and invasion [28], and neuroendocrine differentiation [29].

The Histone Methyltransferase NSD2

NSD2 (nuclear receptor binding SET domain protein 2), also known as WHSC1 (Wolf-Hirschhorn syndrome candidate 1) and MMSET (multiple myeloma SET domain), is a member of the histone methyltransferase NSD family of proteins also including NSD1 and NSD3. NSD2 catalyzes the dimethylation of histone H3 at lysine 36 (H3K36me2), a permissive mark associated with open chromation conformation and active gene transcription [85]. NSD2 was first linked to oncogenesis by the involvement in the t(4; 14) translocation identified in up to 20% of multiple myeloma patients [86]. In the past years, NSD2 has been shown to be overexpressed in a variety of solid tumors including prostate cancer, where it has been found overexpressed in metastatic PCa compared to primary tumors and is associated with biochemical recurrence [1••]. Further In vitro studies strengthened the role of NSD2 in prostate cancer tumorigenesis; it has been shown that NSD2 modulates Twist family bHLH transcription factor 1 (TWIST1) to promote epithelial to mesenchymal transition and invasiveness in prostate cancer cell lines [2]. Moreover, Asangani and colleagues had reported that EZH2 mediates the overexpression of NSD2 and that the oncogenic properties of EZH2 are NSD2 dependent [3]. Interestingly, transcriptional targets of NSD2 in prostate cancer cells are highly enriched for components of the NF-kB-network, including IL-6, IL-8, survivin/Birc5, and VEGFA. In fact, NSD2 has been linked to constitutive activation of NF-kB signaling in CRPC, promoting cancer cell proliferation and survival via an autocrine positive loop in which NSD2 expression is in turn stimulated by inflammatory cytokines, such as TNFα and IL-6, via NF-kB [87].

Very recently, work from Li and collaborators showed that NSD2 is activated in PTEN null tumors by the AKT pathway and that its expression is required for metastatic progression. Mechanistically, AKT-mediated phosphorylation of NSD2 prevents its degradation by CRL4Cdt2 E3 ligase leading to NSD2 stabilization and overexpression. By directly inducing RICTOR expression, NSD2 mediates a positive feedback loop sustaining AKT signaling [1••].

Finally, NSD2 has been shown to physically interact with the AR DNA-binding domain and to be recruited to the enhancer region of the PSA gene and enhance AR transcriptional activity [88], suggesting that NSD2 might be implicated in resistant to ADT or androgen signaling inhibition. Of note is the recent identification of NSD2 as a candidate gene promoting androgen independence through an unbiased insertional mutagenesis screen [89]. In fact, unpublished data and data from our laboratory currently under peer-review for publication strongly suggest that NSD2 is an actionable mechanism in CRPC.

Epigenetic Control of Androgen Receptor Activity

Histone modifying enzymes, and LSD1 in particular, are among the best-known modulators of AR transcriptional activity. LSD1 is an important enzyme involved in AR regulation and prostate cancer that interacts with AR and can stimulate [14••] or suppress [15] the transcriptional expression depending on promoter/enhancer context. This interaction promotes ligand-dependent transcription of AR target genes, resulting in enhanced tumor cell growth. Its coactivator activity seems to be associated with H3K9me1,2 demethylation leading to transcriptional de-repression of AR target genes [14••]. Intriguingly, LSD1 also plays a role as co-repressor, via H3K4me1,2 demethylation [90] and the recruitment of co-repressor complexes. This highlights the dual role of many chromatin remodelers and may explain why translating them to new therapeutics has so far been limited. A possible way forward may be to define the context specificities for this duality. For example, it has been shown that in high androgen levels, AR recruits LSD1 to mediate AR gene silencing [15]; however, this negative feedback loop is apparently disrupted in CRPC, where low androgen levels promote AR overexpression. Additionally, post-transcriptional modifications can regulate LSD1 activity and may become better targets; LSD1 phosphorylation [91] results in a switch of substrate from H3K4me1,2 to H3K9me1,2, and the promotion of its coactivator activity. Jumonji C domain-containing trimethyl lysine demethylases JMJD2A (KDM4A) and JMJD2C (KDM4C) also play a significant role in modulating AR transcriptional activity [30, 31], stimulating ligand-independent gene transcription via H3K9 demethylation. On the contrary, JMJD1A (KDM3A) recruitment to target genes only occurs in the presence of androgens, regulating AR activity and identifying KDM3A-dependent genes involved in androgen response, hypoxia, glycolysis, and lipid metabolism [33], again evidencing the complex balance between chromatin modifying enzymes in controlling different but interconnected cellular processes. Of note is the case of JMJD2B (KDM4B), which is an AR coactivator, emerging as a suitable therapeutic target for the treatment of prostate cancer. JMJD2B controls AR transcriptional activity via demethylation and inhibition of ubiquitination and increased AR stability [34]. Finally, JMJD3 (KDM6B) is progressively overexpressed in metastatic prostate cancer [35].

Histone Acetylation and AR

Acetylated chromatin is generally associated to active transcription and the enzymes regulating this process are histone acetyltransferases (HAT) and deacetylases (HDAC). Accordingly, acetylated histone H3 in the vicinity of AR-bound chromatin has been shown to reduce androgen dependence in castration resistance models [92, 93]. That is the case for canonical HAT like p300 and CREB-binding protein, which, besides canonical histone acetylation activities, have been shown to acetylate the AR and enhance its transcriptional activity [40]. Importantly, two groups have recently independently developed small molecule inhibitors targeting p300/CBP. Lasko and colleagues reported a selective catalytic p300/CBP inhibitor able to downregulate the AR transcriptional program both in castration-sensitive and castration-resistant prostate tumors and to inhibit tumor growth in CRPC xenograft models [94], while Jin and colleagues found that targeting the p300/CBP bromodomain had remarkably similar effetcs [41]. More broadly, a recent study highlights the important role of histone acetylation in prostate cancer beyond active promoters via activation of AR associated enhancers and the increase in chromatin accessibility [95•].

Conversely, a variety of HDACs are also capable of deacetylating the AR and inhibit its activity, for example via regulation of heat-shock protein 90 (Hsp90), a chaperone controlling AR nuclear localization and activation through its acetylation/deacetylation, or sirtuin 1 (SIRT1), which regulates cellular growth through AR deacetylation [42, 43]. In fact, acetylation of H3K18, putatively via downregulation of SIRT2 deacetylase, has been associated to poorer outcome and decreased sensitivity to androgen deprivation therapy (ADT). Finally, at the mechanistic level, the Wu lab has recently demonstrated that HDAC inhibitors can suppress HMGA-driven EMT, reduce tumor growth and metastasis and, importantly, resensitize prostate cancer cells to [96].

The Role of EZH2/Polycomb Repressive Complex in Prostate Cancer

The enhancer of zeste homolog 2 (EZH2) is a critical member of the Polycomb Repressive Complex 2 (PRC2) that regulates histone methylation mainly via lysine 27 at histone H3 (H3K27), a modification associated to transcriptional silencing [97] that is found upregulated in many tumor types. In prostate cancer, its elevated expression associates with poorer outcomes and has therefore been proposed as an oncogene [4, 98]. A major function of EZH2 is to repress lineage-specifying factors, thereby promoting stemness features [99], epithelial-mesenchymal transition (EMT), and ultimately metastatic progression [100]. A wealth of recent evidence has confirmed these previous observation in the prostate cancer field. Back-to-back recent articles in Science by the Sawyers and Goodrich groups demonstrated that lineage plasticity and neuroendocrine differentiation in androgen independence is partly driven by Ezh2 and Sox2 in prostate cancer mouse models carrying loss of function alleles for p53 and Rb tumor suppressors [62••, 63••]. This came to confirm two previous reports by Dardenne and colleagues [64] and by Xu and colleagues [101] showing that N-myc induces EZH2-driven neuroendocrine prostate cancer [64] and it cooperates with E2F1 in castration resistance [101].

Yet, EZH2 has also PRC2-independent roles as coactivator of transcription factors, including an AKT-dependent methylation of the AR, via PI3K/AKT phosphorylation of EZH2 at serine 21 [102], and modulation of AR recruitment to its target sites [103••]. Not surprisingly, EZH2 inhibitors are the focus of intensive development and have been widely tested in vivo [5] and in clinical trials (see Table 2 for details). Beyond a promising drug target, EZH2 and TOP2A have been proposed as prognostic as well as predictive biomarkers of treatment response against EZH2 inhibitors [104].
Table 2

Clinical trials for epigenetic drugs including prostate cancer patients

Trial ID






BET bromodomain inhibitors




NUT midline carcinoma, triple negative breast cancer, non-small cell lung cancer (rearranged ALK or mut KRAS), CPRC, pancreatic ductal adenocarcinoma





NUT midline carcinoma, triple negative breast cancer, non-small cell lung cancer, CRPC





Solid Tumors






Metastatic CRPC (+enzalutamide)





Metastatic CRPC






Solid tumors


Not recruiting




Advanced solid tumors






Advanced cancer, breast cancer, non-small, ell lung cancer, acute myeloid leukemia, multiple myeloma, prostate cancer, small-cell lung cancer, non-Hodgkins lymphoma






Advanced or recurrent solid tumors




BAY 1238097








Advanced cancer


Active, not recruiting




Advanced cancer






Metastatic CRPC (+enzalutamide)






Advanced solid tumors and hematologic malignancy (+abiraterone)



EZH2 and PRC1/2 inhibitors




Advanced solid tumors, non-Hodgkin lymphoma, or histiocytic (EZH2, SMARCB1, or SMARCA4 mutations)





Advanced solid tumors





Advanced solid tumors





Metastatic malignant solid neoplasm


Not recruiting

PRMT5 inhibitor




Diffuse large B cell lymphoma, advanced solid tumors



LSD1/KDM1A inhibitors




Advanced cancer



DNMT inhibitors




Prostate cancer






Metastatic CRPC (+docetaxel, prednisone)











Non-small cell lung cancer, CRPC (+pembrolizumab)


Not yet recruiting

HDAC inhibitors


Pracinostat (SB939)


Metastatic CRPC





Prostate cancer, head and neck cancer, esophageal cancer




Panobinostat (LBH589)


CRPC (+bicalutamide)





Metastatic CRPC





CRPC (+docetaxel and prednisone)





CRPC (+docetaxel and prednisone)





CRPC (+docetaxel and prednisone)




Vorinostat (SAHA, MK0683)


Metastatic CRPC





Metastatic CRPC





Primary prostate cancer (+bicalutamide.)





Non-small-cell lung carcinoma, prostate cancer, bladder cancer, urothelial carcinoma




Mocetinostat (MGCD0103)


Breast cancer, lung cancer, prostate cancer, gastric cancer (+docetaxel)




Entinostat (MS-275)


Advanced solid tumors, lymphoma




Belinostat (PXD101)


Advanced solid tumors, lymphoma





Advanced solid tumors (+5-fluorouracil)



Bromodomain-Containing Proteins in Prostate Cancer

Bromodomain-containing proteins are chromatin readers that recognized mono-acetylated histones and trigger chromatin remodeling to initiate transcription. Mutations and deregulation of BRD-containing proteins is a common feature of a variety of cancers. More than 50% of primary and metastatic prostate tumors and more than 70% of neuroendocrine prostate cancer present genomic alterations in any of the 42 known BRD-containing proteins [105]. Further, BRD-containing proteins have a diversity of catalytic and scaffolding functions and may act as transcription factors, transcriptional co-factors recruiting other proteins in the transcriptional complex, methyltransferases, HATs, Helicases, and ATP-dependent chromatin remodelers, therefore playing a central role in gene expression regulation [106].

The subgroup of BET proteins (bromodomain and extra-terminal), and in particular BRD4, have been the best characterized in prostate cancer, and several inhibitors of BET bromodomains have been developed and are currently in clinical trial (see Table 2). The conserved BET family includes BRD4, BRD2, BRD3, expressed ubiquitously, and BRDT, specifically expressed in the testis. BRD4 recognizes acetylated lysines at enhancers/superenhancer [107••, 108••] and recruits the elongation factor P-TEFb and stimulates RNA polymerase II-dependent transcription [109]. A provocative new finding by Zuber and colleagues with implications in risk assessment shows that tissue-specific SNPs in super-enhancer sequence bound by BRD4 are significantly associated with increased prostate cancer risk and show better enrichment for risk loci than AR [110].

BRD4 physically interacts with high-affinity with the N-terminal domain of AR leading to AR translocation into the nucleus and AR recruitment to target loci, promoting AR activity and expression of AR target genes in CRPC [45•]. A recent study showed that the small molecule BET inhibitor ABBV-075 could disrupt the recruitment of BRD4 at enhancer of AR target genes and repress their expression, whithout affecting AR protein levels [111]. Moreover, BET proteins have a role in resistance to antiandrogens and BET inhibitors can effectively resensitize resistant tumors to enzalutamide [112]. One of these mechanisms of resistance to antiandrogens is the upregulation of the glucocorticoid receptor (GR), and the co-option of the AR regulon, thus favoring CRPC progression by overcoming AR dependency [46, 47, 113].

Beyond AR signaling, BRD4 has been shown to bind to the truncated ERG (ERGΔ39) encoded by the TMPRSS2-ERG fusion, co-regulating the expression of ERG target genes in CRPC, thereby stimulating cell growth and invasion [114]. Additionally, SPOP, an E3 ligase substrate binding protein frequently mutated in prostate cancer, was also reported to target BET proteins for ubiquitination-mediated degradation. Interestingly, SPOP mutants fail to ubiquitinate BET proteins, leading to their stabilization and to resistance to BET inhibitors [48, 115]. This mechanism of resistance causes activation of AKT-mTORC1 signaling and consequently resistance to BET inhibitors can be overcome by combination with AKT inhibitors [116].

It is well known that one of the major aging-associated drivers of prostate carcinogenesis is oxidative stress and its impact on DNA [117]. Interestingly, Hussong and colleagues have recently established a link between BRD4 and oxidative stress response genes in prostate cancer, such as the KEAP1/NRF2 axis and HMOX1, and reactive oxygen species (ROS) production [118].

Other than BET, several BRD-containing proteins have been associated to prostate cancer progression and are at different validation stages for therapeutic targets in mCRPC. TRIM24, tripartite motif-containing protein 24, is an epigenetic reader and transcription co-regulator overexpressed in CRPC and associated to disease recurrence. Recurrent SPOP mutants stabilize TRIM24 [119], enhancing AR signaling and promoting tumor growth via binding with the proteins TIP60 and BRD7 [120], which has led to the proposition of TRIM24 as an essential gene for prostate cancer cell proliferation in CRPC [49].

Finally, the role of chromodomain proteins, and in particular chromodomain helicase DNA-binding protein 1 (CHD1), has in the recent years been elucidated in the context of prostate cancer progression. This H3K4me2-3 epigenetic reader has been reported mutated in 43% of Gleason 7 or higher prostate cancer tumors, associated with ETS gene fusion negative status [121] and its loss related with prostate cancer aggressiveness [50] and DNA repair defects, hence sensitizing tumor cells to PARP inhibitors [51]. More recently, Zhao and colleagues at the DePinho laboratory have demonstrated in PTEN null prostate tumors that CHD1 depletion dramatically suppressed cell proliferation, survival, and tumorigenic potential by activating the pro-tumorigenic TNF-NF-κB gene network [122].

Pioneer Factors in Prostate Cancer Progression

Different from other DNA bound proteins and transcription factors, pioneer factors can access their targets in nucleosomes and in highly compacted chromatin regions, facilitating chromatin accessibility and the recruitment of additional TFs and co-TF and the transcriptional machinery [123]. Among paradigmatic pioneering factors are some of the members of the GATA and FoxA gene families, known mainly for their key role as chromatin-factors during early development [124, 125, 126, 127].

The best-known pioneering factor for its role in prostate cancer is FOXA1. Through the interaction and recruitment of AR to chromatin site, FoxA1 defines and controls the AR cistrome resulting in context-dependent positive or negative regulation [52, 55, 128, 129]. In particular, because FOXA1 activity on chromatin results in increased accessibility [52] and increased chromatin-bound AR, high FOXA1 expression leads to a restricted AR cistrome regulation [53].

GATA genes, and GATA2 in particular, have proved to be crucial for prostate development via modulating AR function [54, 55]. However, despite the role is comparable to that of FoxA1, the mechanisms have shown to be quite different. GATA2 depletion did not seem to have a reprogramming effect on AR binding sites and in fact correlated with a downregulation in AR expression. Accordingly, GATA2 activity in human prostate cancer is strongly associated to AR levels and is hence considered a prostate cancer oncogene. Provocatively, it was found that FOXA1 also has the potential to reprogram GATA2 and act as a pioneering effect for both AR and GATA2, suggesting that FOXA1 regulates a transcriptional network that controls AR-mediated gene expression in prostate cancer [53].

Lineage Plasticity in Prostate Cancer Stem Cells

Aside from their ability to induce pluripotency, the Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC) [130], and other reprograming factors like NANOG or LIN28, have been widely implicated in tumorigenesis in various cancers including the prostate.

SOX2 is required for survival, pluripotency, clonogenicity, and self-renewal of ESCs. A relationship between SOX2 overexpression in tumorigenesis has been established in different types of cancer, including prostate [56] and its expression linked to tumor grade [58]. SOX2 is an epigenetic reprogramming factor and oncogene shown to regulate androgen-independent CRPC proliferation and evasion of apoptosis [57, 58] and to promote tumor metastasis by inducing EMT [59]. Further evidence suggests that SOX2 promotes self-renewal of the CSCs population by acting downstream of EGFR [131]. Importantly, in the recent years, SOX2 activity has been tightly associated to neuroendocrine transdifferentiation from prostate adenocarcinoma cells and the subsequent androgen independence of neuroendocrine prostate cancer phenotypes (NEPC). While the exact mechanisms remain unclear, substantial progress was made over the last couple of years. In particular, Russo and colleagues showed that SOX2 was expressed in NEPC murine models [60] whereas others found its expression restricted to NEPC areas of advanced human prostate cancer [61]. Recent studies by Bishop and collaborators at the Zoubeidi laboratory have shown that SOX2 is transcriptionally regulated by neural transcription factor BRN2 [132••], which in turn is negatively suppressed by the AR, hence revealing an AR-dependent suppression of cell differentiation toward a neuroendocrine AR-independent phenotype. Additional support to the central role of SOX2 in the emergence of NEPC and AR-independence after Enzalutamide treatment came from studies at the Ku and Mu and collaborators at the Sawyers and Goodrich laboratories [62••, 63••].

c-MYC (MYC) is a well-known oncogene proposed as a marker of disease progression in prostate cancer [133] and associated with prostate cancer recurrence and poor prognosis [134]. MYC activation cooperates with loss of PTEN to drive prostate cancer progression [135] and metastasis [136]. MYC proteins also drive epigenetic activation of gene expression in prostate cancer; the PRC2 member EZH2 is directly upregulated by MYC [137] and MYCN, which was shown to be a driver of NEPC [66] by inducing an EZH2-mediated transcriptional program [64]. Additionally, MYC expression was found to be regulated by the histone demethylase JMJD1A, controlling proliferation and survival of prostate cancer cells [138]. MYC also regulates the expression of histone demethylases PHF8 and KDMA3 in NEPC and CRPC [29]. Interestingly, while AR signaling in the normal prostate represses MYC expression, its expression is stimulated by AR during tumorigenesis, [139, 140]. It was also recently reported that MYC overexpression deregulates the AR transcriptional program by altering AR chromatin occupancy and H3K4me1 and H3K27me3 marks distribution, antagonizing clinically relevant AR target genes such as PSA [65].

Oncogenic Pathways Involved in Epigenetic Regulations

Together with the AR, the oncogenic pathways most frequently altered in prostate cancer onset and progression are the RB, PI3K/AKT, and Ras/Raf pathways due to mutations in several members [72]. While the Ras/Raf pathway is activated in 43% of primary and 90% of metastatic prostate cancer, the triggering mechanisms remain to be fully understood. The Whitte laboratory demonstrated a synergistic interaction between Ras pathway activation and AR signaling that leads to elevated EZH2 expression and expand prostate cancer progenitor cells in vivo. It has been long suggested that this pathway is a major contributor of aggressiveness via the activation of EMT transcriptional programs. Nolan and colleagues proposed a model in which the secreted extracellular protein Hsp90 initiates ERK signaling and leads to the recruitment of EZH2 to the E-cadherin promoter and repression of E-cadherin expression, driving epithelial to mesenchymal transition (EMT) and invasion in prostate cancer cells [67]. Additionally, DAB2IP (disabled homolog 2 interacting protein) is a tumor suppressor Ras-GAP that negatively controls Ras-dependent mitogenic signals and modulates TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptors pathways [68, 69, 70]. EZH2-induced DAB2IP silencing activates Ras and NF-kappaB and triggers metastasis [141, 142]. Data from our laboratory showed that concomitant activation of the PI3K and MAPk pathways in mice results in highly aggressive and fully metastatic tumors that are inherently castration resistant [143, 144]. Interestingly, by targeting the PI3K/MAPk pathways with small molecules in vivo, we demonstrated that the drug response network was highly enriched in epigenetic modulators, including SUV39H1, WHSC1, TOP2A, or UHRF1 [145], suggesting that epigenetic control of gene expression plays a central role in the aggressive phenotype imposed by the activation of Ras signaling. Accordingly, we have found that a core signature of chromatin modifiers and DNMTs drive the cancer cell intrinsic mechanisms of metastasis and CRPC (unpublished).

The retinoblastoma tumor suppressor gene RB1 is more commonly loss in metastatic and antiandrogen resistant prostate cancer (74% of cases) and NEPC (90% of cases) [71] than it is in primary tumors (34% of cases) [72]. It has been recently described an activity of Rb1 in the epigenetic regulation of expression, since RB1 directly repress the expression of Sox2 and Ezh2. Consequently, Rb1 loss in prostate cancer lead to EZH2 and Sox2 increase and gene expression widespread changes that leads toward a stem cell-like state that would facilitate the onset of metastasis, neuroendocrine transdifferentiation, and the acquisition of ADT resistance. The authors show that Ezh2 inhibition restores enzalutamide sensitivity in NEPC variants and recurrent prostate cancer cells by opposing lineage transformation [63••]. Furthermore, mutations in TP53 and RB1 tumor suppressor genes can promote a cellular plasticity state mediated by increased expression of SOX2 that, when it is compromised with antiandrogen therapy promotes resistance through lineage switching [62••]. It has also recently been shown that the Hedgehog (HH) signaling pathway and SOX2 co-operate in androgen-independent prostate cancer to promote carcinogenesis [146].

The PTEN/PI3K/AKT pathway is altered in 42% of primary and 100% of metastatic cases; loss of PTEN and activation of the PI3K/AKT signaling pathway are hallmarks of prostate cancer, and cooperate with the activation of the RAS/MAPK pathway to promote EMT and metastatic CRPC development. Epigenetically, it has also been shown that PTEN depletion contributes to a switch from a global H3K27 acetylatilation to H3K27 trimethylation, resulting in increased expression of EZH2 and decrease of the target genes DAB2PI together with negative regulator of cell growth p27KIP1 and p21CIP1 [147]. As mentioned above, increased AKT activity phosphorylates NSD2 at S172, preventing its degradation by CRL4Cdt2 E3 ligase, hence leading to its stabilization, which in turn upregulates RICTOR (mTORC2). This results in further enhancement of AKT signaling in a AKT/NSD2/mTORC2 positive feedback loop that sustains AKT signaling [1••].

Constitutive activation of TGF-β signaling is a well-recognized mechanism for induction of EMT and prostate cancer metastasis development. TGF-β1-induced EMT in prostate cancer is mediated by the histone methyltransferase RbBP5. RbBP5 is a conserved component of the COMPASS/-like complex, which catalyzes the trimethylation of histone H3 lysine 4 that is considered an epigenetic mark of actively transcribed genes. RbBP5 activity is in turn modulated by the binding of SMAD2/3, a downstream signaling factor to the TGF-beta pathway, to the Snail promoter [148]. Snail activates the EMT process by inhibiting transcription of E-cadherin via the recruitment to its promoter of the polycomb repressive complex 2 (PRC2) and the histone methylstranferase G9a, leading to repressive H3K27 and H3K9 methylation [149, 150]. An interesting new perspective was provided recently linking ERG signaling with TGF-β. Data suggest that ERG regulates the transcription of the transcription factor SOX4 and together they cooperate in TGF-β1-induced EMT of prostate cancer cells [151]. This is not surprising taking into account that the oncogenic role of SOX4 has been proposed in several other tumor types. In particular, SOX4 regulates EZH2 expression and chromating remodeling, and is a key component of the PI3K/AKT pathway in prostate cancer. In fact, SOX4 inhibition reduces AKT and β-catenin pathways activation and decreases prostate cancer invasiveness through positive feedback loop between SOX4 and PI3K-AKT-mTOR [152].

Finally, a tyrosine kinase, namely ACK1, has been found to link oncogenic signaling with epigenetic regulation. ACK1 was found upregulated in primary PCa and CRPC [72, 73], correlated with poor prognosis and reported to interact with AR to drive ADT resistance and CRPC growth [74]. A recent study demostrates that ACK1 regulates transcription of AR and AR-v7 via epigenetic regulation. In particular, ACK1 would phosphorylate histone H4 upstream of the AR transcription start site, recruiting the WRD5/MLL2 complex, therefore mediating H3K4 trymethylation and transcriptional activation. Inhibition of ACK1 with a small molecule inhibitor confirms that this epigenetic activity is required to maintain AR transcription and CRPC tumor growth [153].

Drug Development on Epigenetic Regulators as Therapeutic Targets

Mounting evidence from basic and preclinical investigations suggest that targeting key components of the epigenetic machinery will have clinical benefit for cancer patients including prostate cancer ones. Yet, clinical development for those therapies is still very limited. On the one hand, this may be partly due to the inherent difficulty in targeting nuclear effector mechanisms. On the other hand, the fact that most epigenetic master regulators exert their functions over an extensive transcriptional network in a context-dependent manner makes it particularly challenging to achieve cancer cell specificity, thus resulting in significant toxicity. Despite these limitations, a number of drugs are currently in clinical trials at different phases, being BET bromodomain inhibitors, HMT/HDMT inhibitors, DNMT inhibitors, and HDAC inhibitors the focus of most intense drug development efforts. Table 2 summarizes the most relevant ongoing or recently completed clinical trials involving epigenetic drugs.


In view of the accumulated evidenced supporting the key role of the dysregulated epigenome to prostate cancer onset and progression, three mechanisms emerge as the most significant contributors. First, a number of alterations in epigenetic master regulators result in enhanced transcriptional activity and pro-oncogenic role of the Androgen Receptor signaling. This is largely mediated by either remodeling of the chromatin to facilitate AR binding and assembly of the transcriptional complex and posttranslational modifications in the AR itself or essential co-factors resulting in gain of function features. Secondly, the aberrant activation of transcriptional programs tightly associated to developmental pathways and stem features, either via alterations in pioneering factors or pluripotency master regulators, contributes to the acquisition of treatment-resistant phenotypes that are highly aggressive. Finally, a significant number of alterations in epigenetic master regulators also result in the activation of oncogenic signaling pathways that contribute to the aggressiveness and androgen independence in advanced prostate tumors. In summary, the epigenome is emerging as an attractive and plausible target for anticancer therapy in general and prostate cancer in particular. While drug development is still limited, and faces inherent challenges associated with the unique nature of these targets, it seems evident that efficacy of such treatments will be maximized in combination with standard of care treatments for which most lethal prostate cancer ultimately develop resistant mechanism.



This research is supported by funding from the Spanish Ministry of Economy, Industry and Competitiveness (MINECO), which is part of the State Research Agency, through the projects PI16/01070 and CP15/00090. We also acknowledge the support from the European Association of Urology Research Foundation (EAURF/407003/XH), and the Fundacion BBVA-Young Investigator Award. We thank CERCA Program / Generalitat de Catalunya for the institutional support.

Compliance with Ethical Standards

Conflict of Interest

Katia Ruggero, Sonia Farran-Matas, Adrian Martinez-Tebar, and Alvaro Aytes declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Li N, Xue W, Yuan H, Dong B, Ding Y, Liu Y, et al. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest. 2017;127(4):1284–302. This work demonstrates that NSD2 is activated in PTEN null tumors by the AKT pathway and that its expression is required for metastatic progression. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene. 2013;32(23):2882–90.Google Scholar
  3. 3.
    Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2013;49(1):80–93.Google Scholar
  4. 4.
    Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013;4(5):331–41.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget. 2016;7(3):3440–52.Google Scholar
  6. 6.
    Yu T, Wang C, Yang J, Guo Y, Wu Y, Li X. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells. Oncogene. 2017;6(5):):28.Google Scholar
  7. 7.
    Li Q, Li Y, Wang Y, Cui Z, Gong L, Qu Z, et al. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials. Int J Oncol. 2016;48(4):1437–46.CrossRefPubMedGoogle Scholar
  8. 8.
    Askew EB, Bai S, Parris AB, Minges JT, Wilson EM. Androgen receptor regulation by histone methyltransferase suppressor of variegation 3-9 homolog 2 and melanoma antigen-A11. Mol Cell Endocrinol. 2017;443:42–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Vieira FQ, Costa-Pinheiro P, Almeida-Rios D, Graca I, Monteiro-Reis S, Simoes-Sousa S, et al. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets cyclin D2 through H4K20me3. Oncotarget. 2015;6(15):13644–57.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Huang L, Xu AM. SET and MYND domain containing protein 3 in cancer. Am J Transl Res. 2017;9(1):1–14.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015;72(11):2041–59.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    • Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. Elife. 2016;16(5):13964. This paper links for the first time epigenetically driven posttranslational modifications in the AR and ERG transcriptional expression. CrossRefGoogle Scholar
  13. 13.
    Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, et al. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene. 2017;36(9):1223–31.Google Scholar
  14. 14.
    •• Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436–9. This paper links demethylation of a repressive histone mark with androgen-receptor-dependent gene activation. CrossRefPubMedGoogle Scholar
  15. 15.
    Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20(4):457–71.Google Scholar
  16. 16.
    • Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, et al. LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression. Cancer Res. 2017;77(20):5479–90. This study shows that LSD1-mediated epigenetic reprogramming drives CRPC and was associated with the activation of CENPE and other cell-cycle genes. CrossRefPubMedGoogle Scholar
  17. 17.
    Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A. 2007;104(49):19226–31.Google Scholar
  18. 18.
    Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, et al. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget. 2015;6(2):771–88.Google Scholar
  19. 19.
    Stein J, Majores M, Rohde M, Lim S, Schneider S, Krappe E, et al. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. Am J Pathol. 2014;184(9):2430–7.Google Scholar
  20. 20.
    Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, et al. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 2016;76(4):831–43.Google Scholar
  21. 21.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016;113(22):6259–64.Google Scholar
  22. 22.
    Yu L, Wang Y, Huang S, Wang J, Deng Z, Zhang Q, et al. Structural insights into a novel histone demethylase PHF8. Cell Res. 2010;20(2):166–73.Google Scholar
  23. 23.
    Qi HH, Sarkissian M, Hu G-Q, Wang Z, Bhattacharjee A, Gordon DB, et al. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature. 2010;466:503–7.Google Scholar
  24. 24.
    Qiu J, Shi G, Jia Y, Li J, Wu M, Li J, et al. The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation. Cell Res. 2010;20:908–18.Google Scholar
  25. 25.
    Liu W, Tanasa B, Tyurina OV, Zhou TY, Gassmann R, Liu WT, et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature. 2010;466(7305):508–12.Google Scholar
  26. 26.
    Horton JR, Upadhyay AK, Qi HH, Zhang X, Shi Y, Cheng X. Enzymatic and structural insights for substrate specificity of a family of jumonji histone lysine demethylases. Nat Struct Amp Mol Biol. 2009;17:38.CrossRefGoogle Scholar
  27. 27.
    Bjorkman M, Ostling P, Harma V, Virtanen J, Mpindi JP, Rantala J, et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene. 2012;31(29):3444–56.CrossRefPubMedGoogle Scholar
  28. 28.
    Tong D, Liu Q, Liu G, Yuan W, Wang L, Guo Y, et al. The HIF/PHF8/AR axis promotes prostate cancer progression. Oncogene. 2016;5(12):e283.Google Scholar
  29. 29.
    Maina PK, Shao P, Liu Q, Fazli L, Tyler S, Nasir M, et al. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer. Oncotarget. 2016;7(46):75585–602.Google Scholar
  30. 30.
    Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun. 2007;359(3):742–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 2007;9(3):347–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006;125(3):483–95.Google Scholar
  33. 33.
    Wilson S, Fan L, Sahgal N, Qi J, Filipp FV. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells. Oncotarget. 2017;8(18):30328–43.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, et al. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res. 2013;41(8):4433–46.Google Scholar
  35. 35.
    Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res. 2007;17(10):850–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Chin SP, Dickinson JL, Holloway AF. Epigenetic regulation of prostate cancer. Clin Epigenetics. 2011;2(2):151–69.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia. 2013;15(4):373–83.Google Scholar
  38. 38.
    Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004;202(2):233–40.CrossRefPubMedGoogle Scholar
  39. 39.
    Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, et al. Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer. 2014;111(9):1802–9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000;275(27):20853–60.Google Scholar
  41. 41.
    Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, et al. Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Res. 2017;77(20):5564–75.Google Scholar
  42. 42.
    Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26(21):8122–35.Google Scholar
  43. 43.
    Lavery DN, Bevan CL. Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol. 2011;862125(10):28.Google Scholar
  44. 44.
    Damodaran S, Damaschke N, Gawdzik J, Yang B, Shi C, Allen GO, et al. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. BMC Cancer. 2017;17(1):874.Google Scholar
  45. 45.
    • Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278–82. This study reports that BRD4 physically interacts with high-affinity with the N-terminal domain of AR leading to AR translocation into the nucleus and AR recruitment to target loci, promoting AR activity and expression of AR target genes in CRPC. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. elife. 2017;6Google Scholar
  47. 47.
    Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z, et al. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. elife. 2017;6Google Scholar
  48. 48.
    Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med. 2017;23(9):1063–71.Google Scholar
  49. 49.
    Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell. 2016;29(6):846–58.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, et al. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015;75(6):1021–34.Google Scholar
  51. 51.
    Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 2016;17(11):1609–23.Google Scholar
  52. 52.
    Jin HJ, Zhao JC, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun. 2014;5(3972)Google Scholar
  53. 53.
    Zhao JC, Fong KW, Jin HJ, Yang YA, Kim J, Yu J. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene. 2016;35(33):4335–44.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, et al. Fox A1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008;132(6):958–70.Google Scholar
  55. 55.
    Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27(3):380–92.Google Scholar
  56. 56.
    Wong OG, Huo Z, Siu MK, Zhang H, Jiang L, Wong ES, et al. Hypermethylation of SOX2 promoter in endometrial carcinogenesis. Obstet Gynecol Int. 2010;10(682504):9.Google Scholar
  57. 57.
    Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, et al. Sox 2 targets cyclinE, p 27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif. 2012;45(3):207–16.Google Scholar
  58. 58.
    Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013;8(1):11.CrossRefGoogle Scholar
  59. 59.
    Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett. 2013;336(2):379–89.Google Scholar
  60. 60.
    Russo MV, Esposito S, Tupone MG, Manzoli L, Airoldi I, Pompa P, et al. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget. 2016;7(11):12372–85.Google Scholar
  61. 61.
    Esposito S, Russo MV, Airoldi I, Tupone MG, Sorrentino C, Barbarito G, et al. SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression. Oncotarget. 2015;6(19):17121–34.Google Scholar
  62. 62.
    •• Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84–8. This work demonstrates that lineage plasticity and neuroendocrine differentiation in androgen independence is partly driven by Sox2 in prostate cancer mouse models carrying loss of function alleles for p53 and Rb tumor suppressors. CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    •• Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83. This work shows that Sox2 and Ezh2 mediates suppression of prostate cancer lineage plasticity in Rb1 and p53 null tumours. Ezh2 inhibition restores enzalutamide sensitivity in NEPC variants and recurrent prostate cancer cells by opposing lineage transformation. CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate Cancer. Cancer Cell. 2016;30(4):563–77.Google Scholar
  65. 65.
    Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, et al. C-Myc Antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks. EBioMedicine. 2017;18:83–93.Google Scholar
  66. 66.
    Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 2016;29(4):536–47.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Nolan KD, Franco OE, Hance MW, Hayward SW, Isaacs JS. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion. J Biol Chem. 2015;290(13):8271–82.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Bellazzo A, Di Minin G, Collavin L. Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer. Cell Death Differ. 2017;24(1):15–25.CrossRefPubMedGoogle Scholar
  69. 69.
    Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, et al. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene. 2014;33(15):1954–63.Google Scholar
  70. 70.
    Tsai YS, Lai CL, Lai CH, Chang KH, Wu K, Tseng SF, et al. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget. 2014;5(15):6425–36.Google Scholar
  71. 71.
    Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20(4):890–903.Google Scholar
  72. 72.
    Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.Google Scholar
  73. 73.
    van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A. 2005;102(44):15901–6.Google Scholar
  74. 74.
    Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A. 2007;104(20):8438–43.Google Scholar
  75. 75.
    Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009;150(9):3991–4002.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10(2):209–16.CrossRefPubMedGoogle Scholar
  77. 77.
    Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998;58(2):204–9.Google Scholar
  78. 78.
    Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer. 1997;19(2):90–6.Google Scholar
  79. 79.
    Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J. 2003;17(9):1081–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Ashour N, Angulo JC, Andres G, Alelu R, Gonzalez-Corpas A, Toledo MV, et al. A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate. 2014;74(12):1171–82.CrossRefPubMedGoogle Scholar
  81. 81.
    Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, et al. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res. 2013;41(8):4433–46.Google Scholar
  82. 82.
    Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128(3):574–86.Google Scholar
  83. 83.
    Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66(23):11341–7.Google Scholar
  84. 84.
    Battaglia S, Karasik E, Gillard B, Williams J, Winchester T, Moser MT, et al. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer. Clin Epigenetics. 2017;9(82):017–0382.Google Scholar
  85. 85.
    Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ, 3rd, et al. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 2009; 284(49):34283–34295.Google Scholar
  86. 86.
    Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood. 2005;105(10):4060–9.Google Scholar
  87. 87.
    Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012;32(15):3121–31.Google Scholar
  88. 88.
    Kang HB, Choi Y, Lee JM, Choi KC, Kim HC, Yoo JY, et al. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription. FEBS Lett. 2009;583(12):1880–6.Google Scholar
  89. 89.
    Nalla AK, Williams TF, Collins CP, Rae DT, Trobridge GD. Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome. Mol Carcinog. 2016;55(11):1761–71.Google Scholar
  90. 90.
    Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941–53.Google Scholar
  91. 91.
    Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, Friedrichs N, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol. 2008;10(1):53–60.Google Scholar
  92. 92.
    Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One. 2008;3(11):10.Google Scholar
  93. 93.
    Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol. 2006;26(19):7331–41.Google Scholar
  94. 94.
    Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550(7674):128–32.Google Scholar
  95. 95.
    • Valdes-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, et al. Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer. Nat Commun. 2017;8(1):1346. This study highlights the important role of histone acetylation in prostate cancer beyond active promoters via activation of AR associated enhancers and the increase in chromatin accessibility CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene. 2016;35(29):3781–95.Google Scholar
  97. 97.
    Di Croce L, Helin K. Transcriptional regulation by polycomb group proteins. Nat Struct Mol Biol. 2013;20(10):1147–55.CrossRefPubMedGoogle Scholar
  98. 98.
    Melling N, Thomsen E, Tsourlakis MC, Kluth M, Hube-Magg C, Minner S, et al. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Carcinogenesis. 2015;36(11):1333–40.Google Scholar
  99. 99.
    Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125(2):301–13.Google Scholar
  100. 100.
    Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2016;117(2):351–62.Google Scholar
  101. 101.
    Xu H, Xu K, He HH, Zang C, Chen CH, Chen Y, et al. Integrative analysis reveals the transcriptional collaboration between EZH2 and E2F1 in the regulation of cancer-related gene expression. Mol Cancer Res. 2016;14(2):163–72.Google Scholar
  102. 102.
    Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005;310(5746):306–10.Google Scholar
  103. 103.
    •• Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012;338(6113):1465–9. This paper provides compelling evidence that the oncogenic role of Ezh2 in CRPC is partly independent of its repressive function and acts via coactivator functions with key transcription factors including AR CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Labbe DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 2017;23(22):7072–83.CrossRefPubMedGoogle Scholar
  105. 105.
    Urbanucci A, Mills IG. Bromodomain-containing proteins in prostate cancer. Mol Cell Endocrinol. 2017;Google Scholar
  106. 106.
    Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246–62.CrossRefPubMedGoogle Scholar
  107. 107.
    •• Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153(2):320–334.Google Scholar
  108. 108.
    •• Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–19. This two papers provide evidence that disruption of enhancers and superenhancers through BET bromodomain inhibition is a promising therapeutic option in cancer and highlight the key role of this epigenetic master regulator in cancer progression CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523–34.CrossRefPubMedGoogle Scholar
  110. 110.
    Zuber V, Bettella F, Witoelar A, Andreassen OA, Mills IG, Urbanucci A. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics. 2017;18(1):270.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Faivre EJ, Wilcox D, Lin X, Hessler P, Torrent M, He W, et al. Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075. Mol Cancer Res. 2017;15(1):35–44.Google Scholar
  112. 112.
    Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, et al. BET Bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res. 2016;14(4):324–31.Google Scholar
  113. 113.
    Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–22.Google Scholar
  114. 114.
    Blee AM, Liu S, Wang L, Huang H. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget. 2016;7(25):38319–32.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046–54.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23(9):1055–62.Google Scholar
  117. 117.
    Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2):155–62.CrossRefPubMedGoogle Scholar
  118. 118.
    Hussong M, Borno ST, Kerick M, Wunderlich A, Franz A, Sultmann H, et al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis. 2014;5:e1195.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85–9.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. 2009;1793(12):1828–36.Google Scholar
  121. 121.
    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–43.Google Scholar
  122. 122.
    Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017;542(7642):484–8.Google Scholar
  123. 123.
    Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011;25(21):2227–41.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Lee CS, Friedman JR, Fulmer JT, Kaestner KH. The initiation of liver development is dependent on Foxa transcription factors. Nature. 2005;435(7044):944–7.CrossRefPubMedGoogle Scholar
  125. 125.
    Watt AJ, Zhao R, Li J, Duncan SA. Development of the mammalian liver and ventral pancreas is dependent on GATA4. BMC Dev Biol. 2007;7(1):37.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Zhao R, Watt AJ, Li J, Luebke-Wheeler J, Morrisey EE, Duncan SA. GATA6 is essential for embryonic development of the liver but dispensable for early heart formation. Mol Cell Biol. 2005;25(7):2622–31.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Holtzinger A, Evans T. Gata4 regulates the formation of multiple organs. Development. 2005;132(17):4005–14.CrossRefPubMedGoogle Scholar
  128. 128.
    Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138(2):245–56.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390–4.Google Scholar
  130. 130.
    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.Google Scholar
  131. 131.
    Rybak AP, Tang D. SOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells. Cell Signal. 2013;25(12):2734–42.CrossRefPubMedGoogle Scholar
  132. 132.
    •• Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7(1):54–71. This works provides a mechanistic model for neuroendocrine differentiation after AR signaling blockade using patiend-derived models CrossRefPubMedGoogle Scholar
  133. 133.
    Zeng W, Sun H, Meng F, Liu Z, Xiong J, Zhou S, et al. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int J Clin Exp Pathol. 2015;8(2):1878–88.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Rye M, Bertilsson H, Drabløs F, Angelsen A, Bathen T, Tessem M-B. Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer2014. 50 p.Google Scholar
  135. 135.
    Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene. 2012;31(3):322–32.CrossRefPubMedGoogle Scholar
  136. 136.
    Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res. 2016;76(2):283–92.CrossRefPubMedGoogle Scholar
  137. 137.
    Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011;2(9):669–83.CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, et al. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene. 2016;35(19):2441–52.Google Scholar
  139. 139.
    Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci. 2014;10(6):627–42.CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/beta-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate. 2014;74(11):1118–31.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem. 2005;280(23):22437–44.CrossRefPubMedGoogle Scholar
  142. 142.
    Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010;16(3):286–94.CrossRefPubMedPubMedCentralGoogle Scholar
  143. 143.
    Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014;25(5):638–51.Google Scholar
  144. 144.
    Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A. 2013;110(37):E3506–15.Google Scholar
  145. 145.
    Mitrofanova A, Aytes A, Zou M, Shen MM, Abate-Shen C, Califano A. Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. Cell Rep. 2015;12(12):2060–71.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Kar S, Sengupta D, Deb M, Pradhan N, Patra SK. SOX2 function and Hedgehog signaling pathway are co-conspirators in promoting androgen independent prostate cancer. Biochim Biophys Acta. 2017;1863(1):253–65.CrossRefPubMedGoogle Scholar
  147. 147.
    Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, et al. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res. 2014;74(7):2050–61.Google Scholar
  148. 148.
    Li D, Sun H, Sun WJ, Bao HB, Si SH, Fan JL, et al. Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial-mesenchymal transition in prostate cancer cell. Oncotarget. 2016;7(40):65553–67.Google Scholar
  149. 149.
    Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012;122(4):1469–86.Google Scholar
  150. 150.
    Liu S, Ye D, Guo W, Yu W, He Y, Hu J, et al. G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma. Oncotarget. 2015;6(9):6887–901.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Liu Y, Zeng S, Jiang X, Lai D, Su Z. SOX4 induces tumor invasion by targeting EMT-related pathway in prostate cancer. Tumour Biol. 2017;39(5):1010428317694539.PubMedGoogle Scholar
  152. 152.
    Bilir B, Osunkoya AO, WGt W, Sannigrahi S, Lefebvre V, Metzger D, et al. SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. Cancer Res. 2016;76(5):1112–21.CrossRefPubMedGoogle Scholar
  153. 153.
    Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, et al. ACK1/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell. 2017;31(6):790–803.e8.Google Scholar

Copyright information

© The Author(s) 2018
corrected publication May/2018

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Katia Ruggero
    • 1
  • Sonia Farran-Matas
    • 1
  • Adrian Martinez-Tebar
    • 1
  • Alvaro Aytes
    • 1
    • 2
    Email author
  1. 1.Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell)Catalan Institute of Oncology, Bellvitge Institute for Biomedical ResearchBarcelonaSpain
  2. 2.Programs of Cancer Therapeutics Resistance (ProCURE)Catalan Institute of Oncology, Bellvitge Institute for Biomedical ResearchBarcelonaSpain

Personalised recommendations